Buprenorphine's 'ceiling effect' on respiratory depression makes it safer in opioid use disorder (OUD) treatment. This ceiling effect is explained by buprenorphine's pharmacodynamics at the mu opioid receptor (MOR): it is a:

• A Low-affinity full agonist whose plasma levels plateau due to CYP3A4 saturation kinetics preventing toxic accumulation
• B Full agonist at MOR but a potent kappa receptor antagonist that counterbalances respiratory depression centrally
• C Biased agonist preferentially coupling MOR to G-protein pathways over beta-arrestin pathways that mediate respiratory depression
• D High-affinity partial agonist at MOR; above a threshold dose, near-full receptor occupancy is achieved but submaximal intrinsic activity limits further respiratory depression ✓

Explanation

Buprenorphine is a high-affinity (picomolar) partial agonist at the mu opioid receptor. Its submaximal intrinsic efficacy (approximately 40–50% relative to full agonists) means that even when occupying virtually all MOR (achieved at moderate doses due to very high affinity), the maximum biological response plateaus. Respiratory neurons cannot be fully activated, creating the ceiling for respiratory depression. The very high receptor affinity also means naloxone can only partially reverse buprenorphine, requiring higher/repeated doses. The 'ceiling' does not apply equally to analgesia and euphoria, hence its analgesic and substitution utility.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.